ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Lunesta Data Presented at 2005 American Psychiatric Association Meeting Poster Session
Sepracor Inc (Nasdaq: SEPR) today announced that it has presented four LUNESTATM brand eszopiclone posters at the 158th
annual meeting of the American Psychiatric Association (APA) in Atlanta.
Two LUNESTA posters reported the findings of a study in patients with co-existing insomnia and depression. Insomnia symptoms
are reported in 65 percent to 90 percent of individuals with depression.1 An additional poster presented data on LUNESTA's
effect on sleep parameters that impact next-day function, and the results of a crossover study evaluating the safety and
efficacy of LUNESTA versus placebo were also presented.
Adjunctive Eszopiclone With Fluoxetine for Major Depressive Disorder (MDD) and Insomnia: Sleep Effects
The results of a Phase IIIB/IV, 545-patient, double-blind, placebo-controlled, ten-week study evaluating the efficacy and
safety of eszopiclone in patients with major depressive disorder (MDD) and insomnia were presented. In this study, patients
who met DSM-IV2 criteria for both insomnia and MDD (either newly diagnosed or patients who have relapsed), were randomized to
receive open-label PROZAC(R) brand fluoxetine each morning and either double-blind eszopiclone 3 mg (n=270) or placebo
(n=275) nightly for the first eight weeks, followed by a two-week period during which patients discontinued double-blind
treatment but continued receiving fluoxetine.
In this study, patient-reported sleep and daytime function measures were assessed. Sleep efficacy was determined using
patient-reported measures of time to sleep onset, wake time after sleep onset (WASO; a sleep maintenance measurement of the
amount of time spent awake after initially falling asleep and the primary endpoint in this analysis) and total sleep time
(TST). Sleep quality and depth, sense of physical well-being, daytime alertness, ability to function and ability to
concentrate were also measured.
Averaged over the double-blind period, patients treated with eszopiclone showed statistically significant (p
Lunesta Datele prezentate la 2005 American psihice Asociatia Reuniunea Poster Session - Lunesta Data Presented at 2005 American Psychiatric Association Meeting Poster Session - articole medicale engleza - startsanatate